Trial Profile

A Phase 1 Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PF 08046052 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Lava Therapeutics; Seagen

Most Recent Events

26 Feb 2025 Planned End Date changed from 30 Sep 2028 to 3 Jul 2029.
26 Feb 2025 Planned primary completion date changed from 31 Jul 2027 to 3 Jul 2028.
20 Aug 2024 According to LAVA Therapeutics media release, Monotherapy Phase 1 dose escalation study underway to evaluate the safety and tolerability in advanced EGFR-expressing solid tumors.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com